參考文獻(xiàn)/References:
[1] 申浩,丁品勝,魏戌,等.基于文獻(xiàn)的骨質(zhì)疏松癥中醫(yī)證候特征研究[J].中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2018,24(12):1676-1679.
[2] 巢元方.諸病源候論[M].北京:中國醫(yī)藥科技出版社,2011:610.
[3] 張君房.云笈七簽[M].北京:中央編譯出版社,2017:1019.
[4] 孫思邈.千金要方[M].北京:人民衛(wèi)生出版社,1955:652.
[5] 石敏,趙繼榮,薛旭,等.基于“脾主肉、腎主骨”理論探討絕經(jīng)后骨質(zhì)疏松癥的OPG/RANK/RANKL信號調(diào)控機(jī)制[J].中國骨質(zhì)疏松雜志,2019,25(9):1336-1339.
[6] 黃帝內(nèi)經(jīng)素問[M].田代華,整理.北京:人民衛(wèi)生出版社,2005:23.
[7] 王偉,萬雷,柴爽,等.骨質(zhì)疏松癥的中醫(yī)病因病機(jī)和分期治療[J].中醫(yī)正骨,2018,30(2):29-30.
[8] 王咪咪,李林.唐容川醫(yī)學(xué)全書[M].北京:中國中醫(yī)藥出版社,2015.
[9] 李娜,杜麗坤,王冰梅.原發(fā)性骨質(zhì)疏松癥的中醫(yī)證素辨證法[J].中國骨質(zhì)疏松雜志,2019,25(7):1010-1014.
[10] 葛臻,丁閱異.骨質(zhì)疏松癥的中醫(yī)證素分布研究[J].湖南中醫(yī)雜志,2019,35(9):126-127.
[11] 中華醫(yī)學(xué)會骨質(zhì)疏松和骨礦鹽疾病分會.中國骨質(zhì)疏松癥流行病學(xué)調(diào)查及“健康骨骼”專項行動結(jié)果發(fā)布[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2019,12(4):317-318.
[12] 朱輝,鄭洪新.骨質(zhì)疏松癥“從腎論治”古今研究[J].中華中醫(yī)藥學(xué)刊,2011,29(8):1741-1742.
[13] 王擁軍,卞琴,崔學(xué)軍,等.“腎主骨”理論研究的思路與方法[J].上海中醫(yī)藥大學(xué)學(xué)報,2010,24(1):8-12.
[14] 黃宏興,蔡樺,梁祖建,等.骨質(zhì)疏松癥(骨痿)的中醫(yī)臨床路徑研究[J].中國骨質(zhì)疏松雜志,2019,25(1):12-18.
[15] 史曉林,梁博程,李春雯.從“因虛致瘀”論原發(fā)性骨質(zhì)疏松癥病機(jī)[J].中國中西醫(yī)結(jié)合雜志,2019,39(1):111-114.
[16] 吳世偉,顏明輝,張玉龍,等.圍絕經(jīng)期婦女骨質(zhì)疏松癥的中醫(yī)證候與骨折的相關(guān)性分析[J].遼寧中醫(yī)雜志,2019,46(1):99-101.
[17] 李雪,申意偉,張曉峰,等.從“血瘀”論治骨質(zhì)疏松癥之古代方藥研究[J].中醫(yī)藥學(xué)報,2019,47(1):11-14.
[18] 康勝,楊鶇祥,敬一夫,等.從督脈論治骨質(zhì)疏松癥的理論依據(jù)和臨床研究進(jìn)展[J].中華中醫(yī)藥學(xué)刊,2019,37(5):1228-1230.
[19] 趙進(jìn)東,舒儀瓊,劉劍,等.復(fù)方補(bǔ)腎活血顆粒對腎虛血瘀證絕經(jīng)后非老年骨質(zhì)疏松癥患者視覺模擬評分和骨密度影響的臨床觀察[J].中國骨質(zhì)疏松雜志,2018,24(1):98-101.
[20] 白璧輝,謝興文,李鼎鵬,等.近五年來中醫(yī)體質(zhì)類型與骨質(zhì)疏松癥相關(guān)性研究的現(xiàn)狀[J].中國骨質(zhì)疏松雜志,2018,24(9):1229-1235.
[21] 袁麗麗,劉梅潔,柴勇,等.基于中醫(yī)不同辨證方法探討原發(fā)性骨質(zhì)疏松癥病因病機(jī)[J].遼寧中醫(yī)藥大學(xué)學(xué)報,2018,20(10):152-155.
[22] 何升華,任之強(qiáng),王建,等.從血瘀對骨代謝的影響探討血瘀在女性原發(fā)性骨質(zhì)疏松癥發(fā)病中的作用機(jī)制[J].中國骨質(zhì)疏松雜志,2017,23(1):69-73.
[23] 申浩,魏戌,謝雁鳴,等.絕經(jīng)后骨質(zhì)疏松癥骨折危險因素及中醫(yī)癥狀相關(guān)性研究[J].中國中西醫(yī)結(jié)合雜志,2017,37(1):50-56.
[24] 萬雷,黃宏興,鄧偉民,等.廣東省中老年女性骨質(zhì)疏松癥患者骨密度、中醫(yī)證型及其影響因素調(diào)查分析[J].中國骨質(zhì)疏松雜志,2019,25(1):107-112.
[25] 唐中堯,李華,徐祖健.中藥治療骨質(zhì)疏松癥的用藥規(guī)律研究[J].中醫(yī)正骨,2019,31(1):20-22.
[26] 安一方,章軼立,謝雁鳴,等.仙靈骨葆膠囊治療絕經(jīng)后骨質(zhì)疏松癥有效性的系統(tǒng)評價和Meta分析[J].中國骨質(zhì)疏松雜志,2019,25(1):47-61.
[27] 詹魁駿,安艷軍,牟新.補(bǔ)腎中成藥對絕經(jīng)后骨質(zhì)疏松癥骨代謝影響的Meta分析[J].中國骨質(zhì)疏松雜志,2019,25(2):202-211.
[28] 黃晉,李建國,謝興文,等.中藥復(fù)方治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究概況[J].中國骨質(zhì)疏松雜志,2019,25(2):277-280.
[29] 張云飛,安軍偉,龔幼波,等.原發(fā)性骨質(zhì)疏松癥的中醫(yī)藥防治研究進(jìn)展[J].中國骨質(zhì)疏松雜志,2019,25(4):554-558.
[30] 李凱,陳克明.骨質(zhì)疏松癥的中醫(yī)藥防治研究進(jìn)展[J].甘肅醫(yī)藥,2019,38(4):301-303.
[31] 柴勇,趙宏艷,劉紅,等.基于臟腑辨證理論探討骨質(zhì)疏松癥的中醫(yī)治療[J].中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2019,25(3):302-304.
[32] 李建國,謝興文,李寧,等.絕經(jīng)后骨質(zhì)疏松癥的中醫(yī)臟腑認(rèn)識及治療現(xiàn)狀[J].中國中醫(yī)基礎(chǔ)醫(yī)學(xué)雜志,2019,25(3):410-412.
[33] 劉海林.中醫(yī)治療老年骨質(zhì)疏松癥臨床研究進(jìn)展[J].河南中醫(yī),2019,39(5):802-804.
[34] 陳濤,賈世青,黎觀保,等.補(bǔ)腎療法治療骨質(zhì)疏松癥的研究進(jìn)展[J].湖南中醫(yī)雜志,2019,35(5):172-174.
[35] 魏戌,章軼立,謝雁鳴.原發(fā)性骨質(zhì)疏松癥中醫(yī)藥防治策略與研究方法[J].中國中醫(yī)藥信息雜志,2018,25(1):5-9.
[36] 招文華,任輝,沈耿楊,等.骨質(zhì)疏松癥腎陽虛病證結(jié)合模型的研究進(jìn)展[J].中華中醫(yī)藥雜志,2018,33(1):219-223.
[37] 李祥雨,姜勁挺,李建國,等.骨質(zhì)疏松癥中藥防治研究進(jìn)展[J].中國骨質(zhì)疏松雜志,2018,24(2):270-275.
[38] 趙志強(qiáng),閻曉霞.中藥補(bǔ)腎法改善原發(fā)性骨質(zhì)疏松癥臨床癥狀的研究[J].中國骨質(zhì)疏松雜志,2018,24(3):371-375.
[39] 劉遼,程玲,龍瑩瑩,等.金天格膠囊治療原發(fā)性骨質(zhì)疏松的系統(tǒng)評價[J].中成藥,2018,40(11):2606-2612.
[40] 劉慶婧.原發(fā)性骨質(zhì)疏松患者醫(yī)療費用及醫(yī)療資源使用研究[J].中國處方藥,2018,16(9):1-3.
[41] 戴加樂,孫惠萍,胡潔云,等.金天格膠囊聯(lián)合唑來膦酸注射液治療絕經(jīng)后糖尿病骨質(zhì)疏松臨床觀察[J].中華中醫(yī)藥學(xué)刊,2018,36(4):916-919.
[42] 高愛榮,王雅萍,路麗,等.金天格膠囊治療骨質(zhì)疏松癥療效觀察[J].中國骨質(zhì)疏松雜志,2016,22(1):99-101.
[43] 段俊虎.金天格膠囊聯(lián)合經(jīng)皮椎體成形術(shù)治療骨質(zhì)疏松性骨折的療效觀察[J].中國醫(yī)院用藥評價與分析,2015,15(12):1582-1584.
[44] 何保玉,滕濤,劉寶戈,等.金天格膠囊治療原發(fā)性骨質(zhì)疏松癥的臨床療效觀察[J].中國骨質(zhì)疏松雜志,2015,21(2):168-174.
[45] 閔朋,張燕萍,曹洪.CT引導(dǎo)下骨水泥注入輔助人工虎骨粉修復(fù)骨質(zhì)疏松性脊椎壓縮性骨折:骨痂生長及骨愈合評價[J].中國組織工程研究,2015,19(3):335-339.
[46] 張軍,吳林生,孫樹椿,等.金天格膠囊治療原發(fā)性骨質(zhì)疏松癥660例臨床療效[J].中國骨質(zhì)疏松雜志,2005,11(4):490-495.
[47] 趙藝如,魏戌,姜俊杰,等.金天格膠囊治療絕經(jīng)后骨質(zhì)疏松癥的系統(tǒng)評價[J].中國中藥雜志,2019,44(1):186-192.
[48] SUN J,YANG X G,HU Y C.Efficacy of jintiange capsules in the treatment of osteoporosis:a network meta-analysis[J].Orthop Surg,2019,11(2):176-186.
[49] 覃裕,邱冰,朱思剛,等.仙靈骨葆膠囊治療骨質(zhì)疏松癥的療效及其對骨代謝及骨轉(zhuǎn)換指標(biāo)的影響分析[J].中國骨質(zhì)疏松雜志,2015,21(9):1056-1060.
[50] 陳鑫,朱雄白,林文軍,等.仙靈骨葆膠囊治療絕經(jīng)后骨質(zhì)疏松的療效及其機(jī)制研究[J].中國臨床藥理學(xué)雜志,2015,31(10):827-829.
[51] 馬遠(yuǎn)征,王以朋,劉強(qiáng),等.中國老年骨質(zhì)疏松癥診療指南(2018)[J].中國實用內(nèi)科雜志,2019,39(1):38-61.
[52] 王桂倩,廖星,章軼立,等.仙靈骨葆膠囊治療原發(fā)性骨質(zhì)疏松癥隨機(jī)對照試驗的系統(tǒng)評價及Meta分析[J].中國中藥雜志,2017,42(15):2829-2844.
[53] 張蕾,劉晶,劉寶,等.仙靈骨葆治療絕經(jīng)后婦女骨質(zhì)疏松的藥物經(jīng)濟(jì)學(xué)分析[J].中國藥物經(jīng)濟(jì)學(xué),2017,12(2):9-12.
[54] 薛小鑾,陳永法.芪骨膠囊與仙靈骨葆膠囊治療原發(fā)性骨質(zhì)疏松癥的Meta分析[J].中國藥物經(jīng)濟(jì)學(xué),2016,11(11):7-10.
[55] 孫麗,唐漢武.仙靈骨葆膠囊輔助治療骨質(zhì)疏松性疼痛療效與安全性的meta分析[J].中國藥物警戒,2016,13(7):422-425.
[56] 邱貴興,裴福興,胡偵明,等.中國骨質(zhì)疏松性骨折診療指南(骨質(zhì)疏松性骨折診斷及治療原則)[J].中華骨與關(guān)節(jié)外科雜志,2015,8(5):371-374.
[57] 中國老年學(xué)學(xué)會骨質(zhì)疏松委員會中醫(yī)藥與骨病學(xué)科組.中醫(yī)藥防治原發(fā)性骨質(zhì)疏松癥專家共識(2015)[J].中國骨質(zhì)疏松雜志,2015,21(9):1023-1028.
[58] 邢燕,畢宏焱,張倩楠,等.骨質(zhì)疏松常用中成藥介紹[J].中國骨質(zhì)疏松雜志,2013,19(1):83-85.
[59] 黃莉,李悅,邱建利,等.骨疏康治療原發(fā)性骨質(zhì)疏松癥隨機(jī)對照臨床研究Meta分析[J].遼寧中醫(yī)藥大學(xué)學(xué)報,2016,18(4):85-88.
[60] 從飛,劉建,范金柱,等.骨疏康膠囊聯(lián)合骨化三醇和阿侖膦酸鈉治療骨質(zhì)疏松的臨床研究[J].現(xiàn)代藥物與臨床,2016,31(9):1395-1398.
[61] 解春霞,劉敏,江芳超,等.骨疏康顆粒治療穩(wěn)定期慢性阻塞性肺疾病合并骨質(zhì)疏松癥的療效觀察[J].中醫(yī)藥導(dǎo)報,2017,23(2):104-106.
[62] 邱芬.骨疏康顆粒聯(lián)合PKP治療骨質(zhì)疏松性椎體壓縮性骨折的臨床療效觀察[D].福州:福建中醫(yī)藥大學(xué),2017.
[63] 周春,方海姬,谷娜,等.骨疏康顆粒對阿侖膦酸鈉治療骨質(zhì)疏松癥的增效減毒作用研究[J].中國醫(yī)院用藥評價與分析,2019,19(6):679-682.
[64] 趙思怡,黃帆,馮子桐,等.補(bǔ)腎活血類中藥復(fù)方制劑治療絕經(jīng)后骨質(zhì)疏松癥有效性和安全性的Meta分析[J].中國藥房,2019,30(8):1105-1111.
[65] 李東濤,李富玉,王劍,等.骨質(zhì)疏松癥中醫(yī)證候療效評價方法研究[J].中醫(yī)雜志,2013,54(13):1110-1114.
[66] 謝雁鳴,宇文亞,董福慧,等.原發(fā)性骨質(zhì)疏松癥中醫(yī)臨床實踐指南(摘錄)[J].中華中醫(yī)藥雜志,2012,27(7):1886-1890.
[67] WEAVER C M,ALEXANDER D D,BOUSHEY C J,et al.Calcium plus vitamin D supplementation and risk of fractures:an updated meta-analysis from the National Osteoporosis Foundation[J].Osteoporosis Int,2016,27(1):367-376.
[68] TAI V,LEUNG W,GREY A,et al.Calcium intake and bone mineral density:systematic review and meta-analysis[J].BMJ,2015,351:h4183.
[69] REID I R,BOLLAND M J,GREY A.Effects of vitamin D supplements on bone mineral density:a systematic review and meta-analysis[J].Lancet,2014,383(9912):146-155.
[70] EASTELL R,O'NEILL T W,HOFBAUER L C,et al.Postmenopausal osteoporosis[J].Nature reviews Disease primers,2016,2:16069.
[71] COMPSTON J,COOPER A,COOPER C,et al.UK clinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2017,12(1):43.
[72] LORENTZON M,ÃKESSON K,MELLSTRÖM D,et al.Vitamin D treatment and bone health—Swedish guidelines are needed.Recommendations from the Swedish society of osteoporosis clinical expert group[J].Lakartidningen,2014,111(37):1508-1510.
[73] TARANTINO U,IOLASCON G,CIANFEROTTI L,et al.Clinical guidelines for the prevention and treatment of osteoporosis:summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology[J].J Orthop Traumatol,2017,18(Suppl 1):3-36.
[74] 宋宇惠,徐麗,師偉,等.基于絕經(jīng)后女性低骨量人群中醫(yī)證候調(diào)查的鹿角補(bǔ)骨顆粒組方探討[J].山東中醫(yī)雜志,2016,35(9):777-780.
[75] 陳相帆,林翔.中醫(yī)防治絕經(jīng)后脊柱骨質(zhì)疏松癥近況[J].江西中醫(yī)藥,2017,48(8): 75-77.
[76] 蔡榕琪,孟依臨,畢晉,等.冬夏使用補(bǔ)腎中藥治療絕經(jīng)后骨質(zhì)疏松癥臨床研究[J].天津中醫(yī)藥大學(xué)學(xué)報,2019,38(2):139-142.
[77] 戴少川.杜仲壯骨膠囊聯(lián)合雷洛昔芬治療絕經(jīng)后骨質(zhì)疏松癥臨床研究[J].中國骨質(zhì)疏松雜志,2018,24(11):1489-1492.
[78] BRIOT K,ROUX C,THOMAS T,et al.2018 update of French recommendations on the management of postmenopausal osteoporosis[J].Joint Bone Spine,2018,85(5):519-530.
[79] 陳思圓,馮柏淋,郭偉雄,等.六味地黃丸聯(lián)合唑來膦酸治療婦女絕經(jīng)后骨質(zhì)疏松的臨床研究[J].現(xiàn)代藥物與臨床,2018,33(5): 1140-1144.
[80] CHAVASSIEUX P,CHAPURLAT R,PORTERO-MUZY N,et al.Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment[J]. J Bone Miner Res,2019,34(9):1597-1608.
[81] WONG E K,PAPAIOANNOU A.Postmenopausal osteoporosis treatment update[J].Current Treatment Options in Rheumatology,2018,4(2):142-157.
[82] 周昊楠,陳遠(yuǎn)明.葛根素防治絕經(jīng)后骨質(zhì)疏松癥的研究進(jìn)展[J].廣西醫(yī)學(xué),2019,41(7): 878-883.
[83] RADOMINSKI S C,BERNARDO W,PAULA A P,et al.Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis[J].Rev Bras Reumatol Engl Ed.2017,57(Suppl 2):452-466.
[84] KINOSHITA M,ISHIJIMA M,KANEKO H,et al.The increase in bone mineral density by bisphosphonate with active vitamin D analogue is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis[J].Modern Rheumatology,2018,29(1):157-164.
[85] CAMACHO P M,PETAK S M,BINKLEY N,et al.American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016[J].EndocrPract,2016,22(Suppl 4):1-42.
[86] NAKAMURA Y,SUZUKI T1,KAMIMURA M,et al.Alfacalcidol increases the therapeutic efficacy of ibandronate on bone mineral density in Japanese women with primary osteoporosis[J].Tohoku J Exp Med,2017,241(4):319-326.
[87] 莊瓊,向科明.獨活寄生湯聯(lián)合唑來膦酸治療絕經(jīng)后肝腎虧虛型骨質(zhì)疏松癥的療效觀察[J].華西醫(yī)學(xué),2013,28(12):1846-1849.
[88] 張鵬貴,杜耿.獨活寄生湯聯(lián)合唑來膦酸治療絕經(jīng)后骨質(zhì)疏松肝腎虧虛證70例[J].河南中醫(yī),2017,37(8):1446-1448.
[89] WATTS N B.Postmenopausal osteoporosis:a clinical review[J].J J Womens Health(Larchmt),2018,27(9):1093-1096..
[90] TORRENTE-SEGARRA V,ROIG-VILASECA D.Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on“variability of denosumab densitometric response in postmenopausal osteoporosis”[J].Rheumatol Int,2018,38(6):1161-1162.
[91] EMERY C,GOURMELEN J,FAGNANI F,et al.Profile of women initiated on denosumab and pattern of use in a restricted postmenopausal osteoporosis indication:a French database analysis over the period 2013-2014[J].Advances in Therapy,2019,36(4),969-975.
[92] DEEKS E D.Author correction to:Denosumab:a review in postmenopausal osteoporosis[J].Drugs Aging,2018,35(3):261.
[93] WU J,ZHANG Q,YAN G,et al.Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis:a meta-analysis[J].J Orthop Surg Res,2018,13(1):194.
[94] MCCLUNG M R.Drug holidays in women treated for postmenopausal osteoporosis[J].Menopause,2018,25(10):1152-1154.
[95] VANUSHIA T,KIM T,ATHENA T,et al.Severe osteoporosis and stridor[J].BMJ,2018,361:k1905.
[96] HE J B,CHEN M H,LIN D K.New insights into the tonifying kidney-yin herbs and formulas for the treatment of osteoporosis[J].Arch Osteoporos,2017,12(1):14.
[97] LI C,LI Q,LIU R,et al.Medicinal herbs in the prevention and treatment of osteoporosis[J].Am J Chin Med,2014,42(1):1-22.
[98] LIN X,XIONG D,PENG Y Q,et al.Epidemiology and management of osteoporosis in the People's Republic of China:current perspectives[J].Clin Interv Aging,2015,10:1017-1033.
[99] WANG S J,YUE W,RAHMAN K,et al.Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional chinese medicine[J].Curr Pharm Des,2016,22(3):312-320.
[100] WEI X,XU A,SHEN H,et al.Qianggu capsule for the treatment of primary osteoporosis:evidence from a Chinese patent medicine[J].BMC Complement Altern Med,2017,17(1):108.
[101] ZHAI Y K,GUO X,PAN Y L,et al.A systematic review of the efficacy and pharmacological profile of Herba Epimedii in osteoporosis therapy[J].Pharmazie,2013,68(9):713-722.
[102] JIN Y X,WU P,MAO Y F,et al.Chinese herbal medicine for osteoporosis:a meta-analysis of randomized controlled trials[J].J Clin Densitom,2017,20(4):516-525.
[103] 魏戌,謝雁鳴.絕經(jīng)后骨質(zhì)疏松癥中醫(yī)療效評價方法的述評[J].世界中醫(yī)藥,2011,6(5):456-458.
[104] 國家食品藥品監(jiān)督管理總局.中藥新藥治療原發(fā)性骨質(zhì)疏松癥臨床研究技術(shù)指導(dǎo)原則[EB/OL].(2015-11-03)[2019-11-11].http:// www.nmpa.gov.cn/WS04/CL2138/300068.html.
[105] 鄭筱萸.中藥新藥臨床研究指導(dǎo)原則(試行)[M].北京:中國醫(yī)藥科技出版社,2002:356-360.
[106] 邵敏.絕經(jīng)后骨質(zhì)疏松癥患者的生存質(zhì)量評估[J].中國臨床康復(fù),2002,6(23):3472-3475.
[107] 劉健,蔡太生.骨質(zhì)疏松癥生活質(zhì)量量表與健康狀況問卷的相關(guān)性研究[J].中國行為醫(yī)學(xué)科學(xué),2006,15(10):939-940.
[108] 羅賢紅,李雄,王蓉輝.溫陽補(bǔ)腎法對骨質(zhì)疏松骨折患者恢復(fù)期血清骨鈣素、PDGF、sVCAM-1與IGF-1水平影響研究[J].遼寧中醫(yī)雜志,2016,43(4):768-771.
[109] 趙榮,李捷.《內(nèi)經(jīng)》理論在痹證“瘥后防復(fù)”中的應(yīng)用[J].吉林中醫(yī)藥,2015,35(3):223-225.
[110] 王新梅,馬蓉,朱雪蓮,等.補(bǔ)腎調(diào)沖方治療絕經(jīng)后腎虛血瘀型骨質(zhì)疏松療效及對患者細(xì)胞因子、骨生化標(biāo)志物的影響[J].中國骨質(zhì)疏松雜志,2019,25(9):1317-1322.
[111] 杜春瑩,胡肇衡,陳玲,等.阿侖膦酸鈉對絕經(jīng)后骨質(zhì)疏松癥患者骨代謝指標(biāo)的影響[J].中國骨質(zhì)疏松雜志,2014,20(1):22-25.
[112] 楊承鑌,劉忠華,于仁波,等.女性絕經(jīng)后骨質(zhì)疏松癥阿侖膦酸鈉聯(lián)合骨化三醇治療的療效[J].中國骨質(zhì)疏松雜志,2015,21(1):75-79.
[113] 莊華烽,李毅中,王培文,等.唑來膦酸注射液治療絕經(jīng)后原發(fā)性骨質(zhì)疏松的急性期藥物不良反應(yīng)研究[J].中國臨床藥理學(xué)雜志,2019,35(11):1119-1121.
[114] 楊益,文俊恩,趙海,等.唑來膦酸注射液治療絕經(jīng)后骨質(zhì)疏松的臨床研究[J].中國臨床藥理學(xué)雜志,2018,34(16):1953-1956.
[115] 屈強(qiáng),藺改雯,金晶.阿侖磷酸鈉與阿法骨化醇膠丸聯(lián)合用藥治療絕經(jīng)后骨質(zhì)疏松癥療效觀察[J].陜西醫(yī)學(xué)雜志,2015,44(7):906-908.
[116] 卜建龍,徐亮,張品一,等.不同用藥方案阿侖磷酸鈉治療老年性骨質(zhì)疏松癥的臨床療效分析[J].中國骨質(zhì)疏松雜志,2014,20(2):181-184.
[117] 郭麗芳,孟皓波,高愛華,等.唑來磷酸鈉對骨質(zhì)疏松癥病人免疫系統(tǒng)的影響研究[J].內(nèi)蒙古醫(yī)科大學(xué)學(xué)報,2018,40(6):582-585.
[118] XUE D,LI F,CHEN G,et al.Do bisphosphonates affect bone healing?A meta-analysis of randomized controlled trials[J].J Orthop Surg Res,2014,9:45.
[119] EASTELL R,ROSEN C J,BLACK D M,et al.Pharmacological management of osteoporosis in postmenopausal women:an endocrine society* clinical practice guideline[J].J Clin Endocrinol Metab,2019,104(5):1595-1622.
[120] 楊乃龍,劉煥娜,馬學(xué)曉,等.青島地區(qū)特立帕肽治療絕經(jīng)后重度骨質(zhì)疏松癥6個月(階段性)有效性和安全性[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2018,11(5):469-474.
[121] 王璽,羅志秀.六味地黃丸聯(lián)合鮭魚降鈣素對改善絕經(jīng)后骨質(zhì)疏松性疼痛癥狀的臨床研究[J].中國骨質(zhì)疏松雜志,2018,24(11): 1485-1488.
[122] 中華醫(yī)學(xué)會骨質(zhì)疏松和骨礦鹽疾病分會.原發(fā)性骨質(zhì)疏松癥診療指南(2017)[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2017,10(5):413-443.
[123] 林華,陳吉.2017年《英國骨質(zhì)疏松癥預(yù)防和治療臨床指南》解讀(二)[J].中華健康管理學(xué)雜志,2018,12(1):15-20.
[124] 周建烈,劉忠厚.補(bǔ)充鈣和維生素D防治骨質(zhì)疏松癥的全球臨床指南進(jìn)展[J].中國骨質(zhì)疏松雜志,2017,23(3):371-378.
[125] 謝楚海,陳斌偉,郭劍鴻,等.阿法骨化醇與骨化三醇對骨質(zhì)疏松患者HOP、BALP及組織形態(tài)學(xué)的影響[J].中國老年學(xué)雜志,2015,35(19):5590-5591.
[126] 馬燕,龐小芬.骨質(zhì)疏松癥的藥物治療新進(jìn)展[J].醫(yī)學(xué)綜述,2015,21(4):700-702.
[127] 胡健,劉曄.不同劑量骨化三醇聯(lián)合鈣劑對絕經(jīng)后骨質(zhì)疏松患者跌倒風(fēng)險的影響[J].臨床藥物治療雜志,2019,17(4):57-60.
[128] 雷雷,鄭瑞芝,韓雙印,等.唑來膦酸聯(lián)合阿法骨化醇和鈣劑治療骨質(zhì)疏松的臨床療效分析[J].中國骨質(zhì)疏松雜志,2019,25(2):233-235.
[129] SUGIMOTO T,SHIRAKI M,NAKANO T,et al.A randomized,double-blind,placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis[J].Curr Med Res Opin,2019,35(3):447-454.
[130] 邢軍,馬振芳,王亞輝,等.多光譜照射治療中老年維生素D缺乏骨質(zhì)疏松癥臨床觀察[J].康復(fù)學(xué)報,2018,28(2):18-21.
[131] 杜迅,龔雪陽,陳嶠峰.低頻脈沖磁場聯(lián)合阿侖膦酸鈉治療絕經(jīng)后骨質(zhì)疏松癥的療效觀察[J].醫(yī)學(xué)臨床研究,2018,35(10):1948-1949.
[132] 張靈玉,江靜怡,樊瑜波,等.磁場在骨生物學(xué)領(lǐng)域:研究與應(yīng)用中明確和未明確問題[J].中國組織工程研究,2019,23(4):584-590.
[133] 張勇,羅婧,陳貴全.針灸治療絕經(jīng)后骨質(zhì)疏松癥的研究進(jìn)展[J].中華針灸電子雜志,2017,6(4):153-155.
[134] 李凱,陳捷,趙林芬,等.中國人群定量CT(QCT)脊柱骨密度正常參考值的建立和骨質(zhì)疏松癥QCT診斷標(biāo)準(zhǔn)的驗證[J].中國骨質(zhì)疏松雜志,2019,25(9):1257-1262.
[135] 《中國定量CT(QCT)骨質(zhì)疏松癥診斷指南》工作組.中國定量CT(QCT)骨質(zhì)疏松癥診斷指南(2018)[J].中國骨質(zhì)疏松雜志,2019,25(6):733-737.
[136] NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy.Osteoporosis prevention,diagnosis,and therapy[J].JAMA,2001,285(6):785-795.
[137] 劉忠厚.骨礦與臨床[M].北京:中國科學(xué)技術(shù)出版社,2006:14.